Vertex ups guidance again as results exceed estimates

5 November 2024

US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’ presentation of its third-quarter financial results and latest outlook for 2024 as a whole.

Product revenue rose by 12% compared to the same period of 2023, to $2.77 billion, beating the $2.68 billion expected by analysts, according to FactSet. 

The growth was primarily driven by the continued strong performance of Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor), a fixed-dose combination medication used to treat cystic fibrosis. Its sales grew by 14% during the quarter, at nearly $2.59 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical